Ambrx Biopharma Inc. Terminates ADS Program, Simplifies Ownership Structure

Strategic Insights -

Ambrx Biopharma Inc. has announced the termination of its American Depositary Shares (ADS) program, a move expected to simplify the company's ownership structure and reduce costs. The decision to terminate the ADS program, which will be effective upon the listing of NewCo's common stock on the Nasdaq Global Select Market, is seen as a strategic move to increase the company's efficiency and flexibility. Ambrx believes the termination of the ADS program will be beneficial for the company and its shareholders, as it will eliminate the fees associated with holding ADSs and provide greater liquidity to shareholders.

Key Takeaways:

  • Ambrx Biopharma Inc. has filed a Form 8-K report with the U.S. Securities and Exchange Commission, announcing the termination of its ADS program.
  • The ADS program will be terminated effective upon the listing of NewCo's common stock on the Nasdaq Global Select Market, which is expected to be October 11, 2023.
  • The termination of the ADS program will eliminate fees associated with holding ADSs, making it more cost-effective for Ambrx to administer.
  • NewCo will have its shares eligible to be held by certain institutional investors and be included in certain stock indexes that are unavailable as a foreign listed company with an ADS program.
  • The Delaware corporate code and related rules and regulations provide better guidance for the board of directors of NewCo and management, making it easier to execute the company's business strategy.
  • Ambrx expects the termination of the ADS program to increase the company's flexibility and provide greater liquidity to shareholders.

Statistics:

  • Estimated fees to be paid to JPMorgan Chase Bank, N.A. in connection with the ADS Program Termination: $2.1 million.
  • Date of Report: September 22, 2023.
  • Date of Smallest Filing Date Entity: September 18, 2023 (Note: This date is the date of the fee letter between Ambrx and JPM).
  • Nasdaq Global Select Market listing date expected: October 11, 2023.
  • 8-K report filing date: September 25, 2023.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT.
  • Ambrx Biopharma Inc. (Exact name of Registrant as Specified in Its Charter)
  • Cayman Islands 001-40505 N/A (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)
  • 10975 North Torrey Pines Road La Jolla, California 92037 (Address of Principal Executive Offices) (Zip Code)